Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24186261 | 0.91 | ALDH1A1 (0.35) | LMNAALDH1A1 | |
| SCHEMBL14944564 | 0.88 | LMNA (0.40) | LMNACYP17A1CYP19A1ALDH1A1MEN1 | |
| SCHEMBL13464729 | 0.87 | LMNA (0.33) | LMNACYP17A1CYP19A1ALDH1A1MEN1 | |
| SCHEMBL15183179 | 0.84 | CYP17A1 (0.31) | CYP17A1CYP19A1 | |
| SCHEMBL22004244 | 0.81 | LMNA (0.35) | LMNAALDH1A1EPHX2CYP3A4CYP2D6 | |
| SCHEMBL15183217 | 0.81 | LMNA (0.32) | LMNAALDH1A1MEN1KMT2AATM | |
| SCHEMBL15183242 | 0.81 | LMNA (0.32) | LMNAALDH1A1MEN1KMT2AATM | |
| SCHEMBL15183171 | 0.80 | CYP17A1 (0.30) | CYP17A1CYP19A1EPHX2 | |
| SCHEMBL24064299 | 0.80 | LMNA (0.33) | LMNACYP17A1CYP19A1ALDH1A1MEN1 | |
| SCHEMBL15183176 | 0.80 | CYP17A1 (0.33) | CYP17A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220011667-A1 | SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| US-10571805-B2 | Resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220011667-A1 | SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | H1-0, H1-4, CHRM1 | LMNA 4555/4885CYP17A1 2730/4885CYP19A1 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.